CA1279573C - Antimicrobial wound dressing - Google Patents
Antimicrobial wound dressingInfo
- Publication number
- CA1279573C CA1279573C CA000539200A CA539200A CA1279573C CA 1279573 C CA1279573 C CA 1279573C CA 000539200 A CA000539200 A CA 000539200A CA 539200 A CA539200 A CA 539200A CA 1279573 C CA1279573 C CA 1279573C
- Authority
- CA
- Canada
- Prior art keywords
- silver
- wound
- substrate
- article
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/07—Stiffening bandages
- A61L15/14—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Abstract
ANTIMICROBIAL WOUND DRESSINGS
Abstract Antimicrobial wound dressings are provided comprised of a substrate coated with an antimicrobially effective film of a silver salt. These antimicrobial wound dressings are prepared by vapor coating or sputter coating certain silver salts onto a variety of wound dressing substrates to provide superior antimicrobial activity over the prior art. Preferred silver salts are silver chloride and silver sulfate.
Abstract Antimicrobial wound dressings are provided comprised of a substrate coated with an antimicrobially effective film of a silver salt. These antimicrobial wound dressings are prepared by vapor coating or sputter coating certain silver salts onto a variety of wound dressing substrates to provide superior antimicrobial activity over the prior art. Preferred silver salts are silver chloride and silver sulfate.
Description
F.N. 41231 USA 6A
ANTIMIcRosIAL WOUND ~RESSINGS
Field of the Invention This invention relates to a wound dressing using a silver salt to impart antimicrobial activity to the dressing.
Background of the Inve tion Silver and silver compounds have long been known for their antimicrobial properties. See Dis_nfection, Sterilization, and Preservation, p. 375 (Seymour slOck 3rd edition, Lea ~ Febiger, Philadelphia, 1983) (chapter 18 authored by N. Grier, entitled "Silver and Its Compounds").
Silver and silver compounds have been incorporated into a number of wound dressing articles. In particular, various wound dressing substrates have been coated with metallic silver. UK Patent Application GB 2 134 791 A describes a surgical dressing prepared by vapor coating or sputter coating Sphagnum moss with metallic silver or a silver/carbon composite. European Patent Application 0 099 758 describes a composite wound dressing comprising a semipermeable membrane, a permeable layer and a biodegradable layer wherein the permeable layer may be fabric coated, impregnated or plated with silver. U.S.
Patent 2,934,066 describes a metallized bandaging material prepared by vapor coating metallic silver onto a fiber fleece. U.S. Patent 4,419,091 describes an electro~e for ion therapy comprising a substrate of polymer fibers wherein each of the fibers is coated with silver.
Other means of providing silver or a silver salt at the site of a wound have also been used in wound dressings. U.S. Patent 4,340,043 describes an adhesive-coated liquid-impervious moisture-vapor permeable thin polymer sheet which has an antibacterial silver salt incorporated into the adhesive. U.S. Patent 3,830,908 ,,~, 3l'~7~S73 describes a synthetic plastic sheet powder-coated with an organic silver salt allantoin complex. U.S. Patent 3,800,~92 describes a laminated collagen foam film dressing with finely divided metallic silver impregnated in the collagen layer. U.S. Patent 4,446,124 describes a wound S dressing comprising silver sulfadiazine incorporated in animal tissue, e.g. pigskin. Genetic Laboratories, Inc. is currently marketing a product called E-Z DERM temporary skin substitute for the treatment of burns. This product is a biosynthetic wound dressing having silver nitrate incorporated therein.
While the prior art described above has solved various problems encountered in the art of antimicrobial wound dressings, they do not possess the advantages of the wound dressings of this invention.
Summary of the Invention The present invention relates to an article useful as a wound dressing comprising a conformable substrate coated with an antimicrobially effective film of a silver salt. As used herein, an antimicrobially effective film is a film which exhibits a statistically significant improvement in the antimicrobial activity as compared with the corresponding control and as measured by the in vitro or in vivo tests described for the examples below. It has been found that a film coating of certain silver salts is more effective than a powder coating and that only certairi silver salts yield an antimicrobially effective film.
The preferred emhodiment is an adhesive-coated thin film dressing bearing a film of silver chloride or - silver sulfate deposited on the adhesive-coated thin film ; dressing by vapor or sputter coating.
It has been found that the dressings of this invention having an antimicrobially effective film of a silver salt are more efficient, i.e., have greater antimicrobial activity while using less silver salt, than conventional wound dressings using silver salts.
'`
, .':
1'~'79573 his invention also relates to methods of pre-paring wound dressings as described above by vapor coating or sputter coating a substrate with an antimicrobially effective amount of a silver salt selected from the group consisting of silver bromide, silver fluoride, silver chloride, silver nitrate, silver sulfate, silver alkylcarboxylate, silver sulphadiazine or silver arylsulfonate.
- ~rief Descriptio _of the Drawin~
Figure 1 shows an exploded view of a conventional wound dressing adapted to prepare an antimicrobial wound dressing of this invention.
Figure 2 shows an exploded view of wound dressing prepared from the adapted dressing of Figure 1.
lS Figures 3-5 show plan views of various patterns of antimicrobially effective films of a silver salt on a substrate.
. .
Detailed ~escription_of_the Invention To prepare a wound dressing of this invention, an antimicrobially effective film of silver salt is formed on the surface of a conformable substrate. The film of silver salt may be continuous or discontinous so long as amounts of silver salts sufficient to have measurable antimicrobial activity are present. When the conformable substrate is fibrous, it is likely that the film is discontinuous with respect to the surface as a whole, but continuous with respect to portions of individual fibers.
The film is preferably deposited on the substrate by vapor or sputter coating techniques. In vapor coating, an amount of salt is vaporized and allowed to condense upon the surface of a substrate to form a film. In sputter coating, material is removed from a silver salt target, carried by a plasma, and deposited on the substrate to form a film. On a fibrous substrate, the film will generally coat at least a portion of individual fibers exposed on the ;
~'~79~;7~3 surface of the substrate. While vapor or sputter coating of a pre-formed fibrous substrate is preferred, individual fibers can be coated witll the film and then worked, e.g.
blown, woven or knitted, into a fibrous substrate bearing an antimicrobially effective film.
The following are examples of suitable silver salts useful in the practice of the present invention:
silver bromide, silver fluoride, silver chloride, silver nitrate, silver sulfate, silver alkylcarboxylate, si-lver sulphadiazine or silver arylsulfonate. Silver alkyl carboxylates are the silver salts of alkylcarboxylic acids preferably having from 1-12 aliphatic carbon atoms, more preferably 1-4 aliphatic carbon atoms, e.g. silver acetate.
The aryl group of the arylsulfonate salts is an aromatic radical, e.g., optionally substituted phenyl or naphthyl, preferably alkaryl having l to 12 aliphatic carbon atoms, more preferably alkylphenyl having from 1 to 4 aliphatic carbon atoms, e.g., p-toluenesulfonate. Preferred salts are silver chloride and silver sulfate. It has been found that silver oxide and silver carbonate decompose when subjected to the energy necessary to vaporize or sputter.
Silver iodide and silver sulfide can be deposited as films on a substrate by vapor or sputter coating, but such films have been found to be antimicrobially ineffective in that their films exhibited antimicrobial activity in vitro equivalent to the control having no film of a silver salt.
The substrate must be sufficiently conformable to conform to the contours of skin to which it will be applied as a wound dressing. The substrate is preferably a fabric or a polymeric film or foam having a tensile modulus of 30 less than about 400,000 psi as measured by ASTM D-638 and D-882, preferably less than about 300,Q00 psi. The substrate may be chosen, for example, from the following:
non-woven meshes such as CarelleR and Nylon 9oR (both registered trademarks of Carolina Formed Fabrics i 35 Corporation), and N-TerfaceR (a registered trademark of ~` Winfield Laboratories, Inc., Richardson, Texas); woven .
1;~'7~5~
meshes of fiberglass or acetate; gauze; polyurethane foams such as HypolR (a registered trademark of W.R. Grace ~ Co., New York, NY); composite wound dressings such as MicropadR
(a registered trademark of 3M Company, St. Paul, Minnesota), and siobraneR (a registered trademark of Woodroof Laboratories, Inc., Santa Ana, California); and adhesive-coated, thin film dressings such as TegadermR (a registered trademark of 3M Company, St. Paul, Minnesota), and OpSiteR (a registered trademark of Smith and Nephew Inc., Columbia, SC). Currently preferred are adhesive-coated thin film dressings, polyurethane foam dressings and woven acetate meshes.
The substrate may be vapor coated using standard techniques. In particular a convenient method of vapor ; coating is accomplished as follows. The substrate to be coated is covered with a mask in which the pattern to be vapor coated has been cut out. In the case of wound dressings with an adhesive coating and a release liner, the release liner may conveniently be used as the mask as shown in Figure 1. Figure 1 shows an exploded view of a conventional wound dressing available from 3M Co. under the tradename TegadermTM brand surgical dressing that has been adapted for the manufacture of an antimicrobial wound dressing of this invention. The release liner is removed from the face of dressing 1 coated with adhesive. Weed 2 is removed, e.g. by stamping, fLom the liner to form mask 3. Mask 3 is then relaminated to dressing 1 leaving portion 4 of the adhesive-coated face of dressing 1 exposed. The dressing is then fastened to a concave metal support (not shown) sheet with a radius, e.g., 20 inch, of curvature. This metal support sheet with the attached dressing is suspended within an evacuable vessel, e.g., a bell jar, concave side down and at a suitable height, e.g., 20 inches, above a crucible. The material to be vaporized is placed in the crucible. The bell housing is lowered to its base and a vacuum, e.g., 10-4 to 10-7 Torr, is created to remove substantia]ly all air and water molecules, which 79~73 would interfere with the vapor coating process. The material is then vaporized by heating it to its melting point with an electron beam. The rate of vaporization can be controlled by the amount of energy applied to the crucible via the electron beam. A crystal monitor receives the same level of material deposition as the dressing and electronically relays the thickness of the layer being deposited. The concave nature of the support sheet to which the dressing is applied helps to assure that all dressings being vapor coated in a particular batch are receiving equivalent levels of deposition.
The coating may range broadly in thickness. A
general]y preferred range is from about 50 Angstroms to about 2,000 Angstroms depending on the silver salt which is being used. When the salt is silver chloride or silver 15 sulfate, the preferred range is about 50 to about 500 Angstroms.
Wourld dressings of the invention may also be prepared by sputter coating using standard techniques.
As shown in Figure 2, dressing l, as a result of the vapor coating procedure described above, bears square pattern 5 of an antimicrobial layer of a silver salt. A
substitute release liner 6 can then be laminated to ~- antimicrobial wound dressing 1 to protect the dressing prior to use.
The pattern of the silver salt deposition on the substrate may be varied by varying the pattern cut into the mask. The pattern may be a simple one, e.g., square pattern 5 as shown in Figure 1, or it may be tailored for a specific wound application as shown in Figures 2-4.
In Figure 3, the film of silver salt forms ring 7 which can be centered over a percutaneous puncture site on the skin of a patient to antimicrobially protect such a wound.
In Figure 4, the film is in the form of a grid 8 which reduces the amount of silver salt needed to protect a large wound surface such as an abrasion.
3~7~7~3 In Figure 5, the film is in the form of parallel bars 9 which can be positioned on the skin of a patient with an incisional wound between the bars to antimicrobially protect such a wound.
Examples In V_tro Testing The antimicrobial properties of the WOUII~ dressings of this invention are demonstrated in vitro using standard techniques as described below. Pl~iglass chambers were constructed with two shelves each containing six circular wells (1.5 inch diameter by 0.25 inch deep). A one-eighth inch solid plexiglass sheet was fastened to the bottom side of each of the sheIves. To prepare for use, the shelf with the wells was placed upside down, the dressing being tested was placed over the well, and finally the solid plexiglass sheet was placed on top of the dressings and fastened in place. When turned right side up, the dressings were sandwiched between and supported from underneath by this bottom plate. Each well was then filled with 3.0 ml of nutrient broth (available from Difco Laboratories).
Inoculation of each well with the microbe being studied was then accomplished by adding a 0.1 ml ~approximately 2 x 1~3 colony forming units) suspension of the microl)es in sterile water. Incubation occurred for 24 hours at 37C in a humidified chamber. At the end of the incubation period the entire volume of each well was placed in a sterile test tube, vortexed, and serial one-hundred fold dilutions (10 to 10-6) were made for streaking onto sheep blood agar plates. Quantitative counts of colony forming units were made from these plates after 24 hours of incubation at 37C. Standard microbial techniques were used in maintaining stock cultures of organisms as well as preparing inoculums. Special media were used when sheep blood agar plates were not appropriate, e.g. Proteus vulgarls was plated onto eosin methylene blue (5% agar) plates to prevent colony spreading.
~2~ 73 In Vivo Testing The antimicrobial properties of the wound dressings of the invention are demonstrated in vivo using standard techni~ues as described below. Female Yorkshire pigs (Sus scrofa) were given preanesthetic doses of atropine sulfate and ketamine. Surgical plane anesthesia was induced with a gaseous mixture of halothane, nitrous oxide, and oxygen through an endotracheal tube. The dorsal ; skin was then washed, shaved, and swabbed with several applications of BetadineR (a registered trademark of the Purdue Frederick Company). The back of the pig was then covered with sterile surgical drapes leaving the setadineR
covered skin exposed. The final application of setadineR
was then repeatedly rinsed with sterile water to remove all traces of setadine , thus resulting in a sterile surgical 15 field. A 7.0 cm by 10.0 cm grid pattern was marked off on the skin to accommodate 16 dressings (6 cm by 7 cm). In the center of each grid, a l cm2 wound was created using a keratome. These wounds were approximately 0.5 to 1.0 mm deep. Each wound was then inoculated with 10~ liter (approximately 2 x 103 colony forming units) of the culture being tested. Immediately after inoculation, the wound dressing being tested was placed over the wound site.
Contrc71 wounds were covered with identical dressings which had not been coated with a silver salt. These inoculated wounds were left intact for 48 hours. Total surgical biopsy of the wounds occurred 48 hours post inoculation.
This biopsy consisted of removing the exudate from underneath the wound by sterile sylinge aspiration, swab removal of surface wound material, and surgical excision of the entire wound to a depth of approximately 3 mm. All samples from a single wound were placed in a sterile homogenizing tube, 3.0 ml of sterile phosphate buffered saline was added and then the samples were hand ground.
One-hundred fold dilutions of this homogenate were then plated out on sheep blood agar plates. The plates were incubated for 24 hours then quantitatively analyzed for the number of colony forming units per wound.
~^ .
~lZ~573 g It should be noted that moist healing conditions should be maintained in vivo to prevent the formation of a scab which can shield the bacteria of the colony from the antimicorbial film of a silver salt and thereby render the in vivo test inaccurate.
~o _Coating Procedure The articles described in the following examples were vapor coated in accordance with the procedure described above wherein the particulars set forth in the exemplary clauses (denoted hy e.g.) were those actually employed to prepare the articles described below.
The following examples are provided to illustrate the invention, but are not intended to limit the invention.
Examples 1-8 and Cornparative Examples A-D
TegadermR B _nd Dressing Vapor ~oated with Various Silver Salts The adhesive-side release liner was removed from a sample of TegadeLmR brand adhesive-coated, thin-film dressing and a 6.25 cm2 square was cut out of the release liner. This liner was then reapplied and the sample was subjected to vapor coating as described with the desired silver compound. However, the silver oxide of Example A
and the silver carbonate of Example s decomposed upon exposure to the electron beam used to vaporize the other silver salt samples. All samples were then tested for ln vitro efficacy against Staphylococcus aureus as described above. The results are summarized in Ta~le 1.
The efficacy ratings assigned in Table 1 are based on the following scale:
Efficacy Rating:
I = less than 103 colony forming units/ml II = 10 to 105 colony forming units/ml III = 106 to 107 colony forming units/ml IV = greater than or equal to 10 colony forming units/ml which is equivalent to the control Y~: ~
~;~7~
In vitro Efficacy of Vapor Coated Tegaderm~ Brand Dressing Against Staphylococcus aureus Film Thickness Efficacy 5 Example Compound (A) Rating 1 Silver fluoride 500 II
ANTIMIcRosIAL WOUND ~RESSINGS
Field of the Invention This invention relates to a wound dressing using a silver salt to impart antimicrobial activity to the dressing.
Background of the Inve tion Silver and silver compounds have long been known for their antimicrobial properties. See Dis_nfection, Sterilization, and Preservation, p. 375 (Seymour slOck 3rd edition, Lea ~ Febiger, Philadelphia, 1983) (chapter 18 authored by N. Grier, entitled "Silver and Its Compounds").
Silver and silver compounds have been incorporated into a number of wound dressing articles. In particular, various wound dressing substrates have been coated with metallic silver. UK Patent Application GB 2 134 791 A describes a surgical dressing prepared by vapor coating or sputter coating Sphagnum moss with metallic silver or a silver/carbon composite. European Patent Application 0 099 758 describes a composite wound dressing comprising a semipermeable membrane, a permeable layer and a biodegradable layer wherein the permeable layer may be fabric coated, impregnated or plated with silver. U.S.
Patent 2,934,066 describes a metallized bandaging material prepared by vapor coating metallic silver onto a fiber fleece. U.S. Patent 4,419,091 describes an electro~e for ion therapy comprising a substrate of polymer fibers wherein each of the fibers is coated with silver.
Other means of providing silver or a silver salt at the site of a wound have also been used in wound dressings. U.S. Patent 4,340,043 describes an adhesive-coated liquid-impervious moisture-vapor permeable thin polymer sheet which has an antibacterial silver salt incorporated into the adhesive. U.S. Patent 3,830,908 ,,~, 3l'~7~S73 describes a synthetic plastic sheet powder-coated with an organic silver salt allantoin complex. U.S. Patent 3,800,~92 describes a laminated collagen foam film dressing with finely divided metallic silver impregnated in the collagen layer. U.S. Patent 4,446,124 describes a wound S dressing comprising silver sulfadiazine incorporated in animal tissue, e.g. pigskin. Genetic Laboratories, Inc. is currently marketing a product called E-Z DERM temporary skin substitute for the treatment of burns. This product is a biosynthetic wound dressing having silver nitrate incorporated therein.
While the prior art described above has solved various problems encountered in the art of antimicrobial wound dressings, they do not possess the advantages of the wound dressings of this invention.
Summary of the Invention The present invention relates to an article useful as a wound dressing comprising a conformable substrate coated with an antimicrobially effective film of a silver salt. As used herein, an antimicrobially effective film is a film which exhibits a statistically significant improvement in the antimicrobial activity as compared with the corresponding control and as measured by the in vitro or in vivo tests described for the examples below. It has been found that a film coating of certain silver salts is more effective than a powder coating and that only certairi silver salts yield an antimicrobially effective film.
The preferred emhodiment is an adhesive-coated thin film dressing bearing a film of silver chloride or - silver sulfate deposited on the adhesive-coated thin film ; dressing by vapor or sputter coating.
It has been found that the dressings of this invention having an antimicrobially effective film of a silver salt are more efficient, i.e., have greater antimicrobial activity while using less silver salt, than conventional wound dressings using silver salts.
'`
, .':
1'~'79573 his invention also relates to methods of pre-paring wound dressings as described above by vapor coating or sputter coating a substrate with an antimicrobially effective amount of a silver salt selected from the group consisting of silver bromide, silver fluoride, silver chloride, silver nitrate, silver sulfate, silver alkylcarboxylate, silver sulphadiazine or silver arylsulfonate.
- ~rief Descriptio _of the Drawin~
Figure 1 shows an exploded view of a conventional wound dressing adapted to prepare an antimicrobial wound dressing of this invention.
Figure 2 shows an exploded view of wound dressing prepared from the adapted dressing of Figure 1.
lS Figures 3-5 show plan views of various patterns of antimicrobially effective films of a silver salt on a substrate.
. .
Detailed ~escription_of_the Invention To prepare a wound dressing of this invention, an antimicrobially effective film of silver salt is formed on the surface of a conformable substrate. The film of silver salt may be continuous or discontinous so long as amounts of silver salts sufficient to have measurable antimicrobial activity are present. When the conformable substrate is fibrous, it is likely that the film is discontinuous with respect to the surface as a whole, but continuous with respect to portions of individual fibers.
The film is preferably deposited on the substrate by vapor or sputter coating techniques. In vapor coating, an amount of salt is vaporized and allowed to condense upon the surface of a substrate to form a film. In sputter coating, material is removed from a silver salt target, carried by a plasma, and deposited on the substrate to form a film. On a fibrous substrate, the film will generally coat at least a portion of individual fibers exposed on the ;
~'~79~;7~3 surface of the substrate. While vapor or sputter coating of a pre-formed fibrous substrate is preferred, individual fibers can be coated witll the film and then worked, e.g.
blown, woven or knitted, into a fibrous substrate bearing an antimicrobially effective film.
The following are examples of suitable silver salts useful in the practice of the present invention:
silver bromide, silver fluoride, silver chloride, silver nitrate, silver sulfate, silver alkylcarboxylate, si-lver sulphadiazine or silver arylsulfonate. Silver alkyl carboxylates are the silver salts of alkylcarboxylic acids preferably having from 1-12 aliphatic carbon atoms, more preferably 1-4 aliphatic carbon atoms, e.g. silver acetate.
The aryl group of the arylsulfonate salts is an aromatic radical, e.g., optionally substituted phenyl or naphthyl, preferably alkaryl having l to 12 aliphatic carbon atoms, more preferably alkylphenyl having from 1 to 4 aliphatic carbon atoms, e.g., p-toluenesulfonate. Preferred salts are silver chloride and silver sulfate. It has been found that silver oxide and silver carbonate decompose when subjected to the energy necessary to vaporize or sputter.
Silver iodide and silver sulfide can be deposited as films on a substrate by vapor or sputter coating, but such films have been found to be antimicrobially ineffective in that their films exhibited antimicrobial activity in vitro equivalent to the control having no film of a silver salt.
The substrate must be sufficiently conformable to conform to the contours of skin to which it will be applied as a wound dressing. The substrate is preferably a fabric or a polymeric film or foam having a tensile modulus of 30 less than about 400,000 psi as measured by ASTM D-638 and D-882, preferably less than about 300,Q00 psi. The substrate may be chosen, for example, from the following:
non-woven meshes such as CarelleR and Nylon 9oR (both registered trademarks of Carolina Formed Fabrics i 35 Corporation), and N-TerfaceR (a registered trademark of ~` Winfield Laboratories, Inc., Richardson, Texas); woven .
1;~'7~5~
meshes of fiberglass or acetate; gauze; polyurethane foams such as HypolR (a registered trademark of W.R. Grace ~ Co., New York, NY); composite wound dressings such as MicropadR
(a registered trademark of 3M Company, St. Paul, Minnesota), and siobraneR (a registered trademark of Woodroof Laboratories, Inc., Santa Ana, California); and adhesive-coated, thin film dressings such as TegadermR (a registered trademark of 3M Company, St. Paul, Minnesota), and OpSiteR (a registered trademark of Smith and Nephew Inc., Columbia, SC). Currently preferred are adhesive-coated thin film dressings, polyurethane foam dressings and woven acetate meshes.
The substrate may be vapor coated using standard techniques. In particular a convenient method of vapor ; coating is accomplished as follows. The substrate to be coated is covered with a mask in which the pattern to be vapor coated has been cut out. In the case of wound dressings with an adhesive coating and a release liner, the release liner may conveniently be used as the mask as shown in Figure 1. Figure 1 shows an exploded view of a conventional wound dressing available from 3M Co. under the tradename TegadermTM brand surgical dressing that has been adapted for the manufacture of an antimicrobial wound dressing of this invention. The release liner is removed from the face of dressing 1 coated with adhesive. Weed 2 is removed, e.g. by stamping, fLom the liner to form mask 3. Mask 3 is then relaminated to dressing 1 leaving portion 4 of the adhesive-coated face of dressing 1 exposed. The dressing is then fastened to a concave metal support (not shown) sheet with a radius, e.g., 20 inch, of curvature. This metal support sheet with the attached dressing is suspended within an evacuable vessel, e.g., a bell jar, concave side down and at a suitable height, e.g., 20 inches, above a crucible. The material to be vaporized is placed in the crucible. The bell housing is lowered to its base and a vacuum, e.g., 10-4 to 10-7 Torr, is created to remove substantia]ly all air and water molecules, which 79~73 would interfere with the vapor coating process. The material is then vaporized by heating it to its melting point with an electron beam. The rate of vaporization can be controlled by the amount of energy applied to the crucible via the electron beam. A crystal monitor receives the same level of material deposition as the dressing and electronically relays the thickness of the layer being deposited. The concave nature of the support sheet to which the dressing is applied helps to assure that all dressings being vapor coated in a particular batch are receiving equivalent levels of deposition.
The coating may range broadly in thickness. A
general]y preferred range is from about 50 Angstroms to about 2,000 Angstroms depending on the silver salt which is being used. When the salt is silver chloride or silver 15 sulfate, the preferred range is about 50 to about 500 Angstroms.
Wourld dressings of the invention may also be prepared by sputter coating using standard techniques.
As shown in Figure 2, dressing l, as a result of the vapor coating procedure described above, bears square pattern 5 of an antimicrobial layer of a silver salt. A
substitute release liner 6 can then be laminated to ~- antimicrobial wound dressing 1 to protect the dressing prior to use.
The pattern of the silver salt deposition on the substrate may be varied by varying the pattern cut into the mask. The pattern may be a simple one, e.g., square pattern 5 as shown in Figure 1, or it may be tailored for a specific wound application as shown in Figures 2-4.
In Figure 3, the film of silver salt forms ring 7 which can be centered over a percutaneous puncture site on the skin of a patient to antimicrobially protect such a wound.
In Figure 4, the film is in the form of a grid 8 which reduces the amount of silver salt needed to protect a large wound surface such as an abrasion.
3~7~7~3 In Figure 5, the film is in the form of parallel bars 9 which can be positioned on the skin of a patient with an incisional wound between the bars to antimicrobially protect such a wound.
Examples In V_tro Testing The antimicrobial properties of the WOUII~ dressings of this invention are demonstrated in vitro using standard techniques as described below. Pl~iglass chambers were constructed with two shelves each containing six circular wells (1.5 inch diameter by 0.25 inch deep). A one-eighth inch solid plexiglass sheet was fastened to the bottom side of each of the sheIves. To prepare for use, the shelf with the wells was placed upside down, the dressing being tested was placed over the well, and finally the solid plexiglass sheet was placed on top of the dressings and fastened in place. When turned right side up, the dressings were sandwiched between and supported from underneath by this bottom plate. Each well was then filled with 3.0 ml of nutrient broth (available from Difco Laboratories).
Inoculation of each well with the microbe being studied was then accomplished by adding a 0.1 ml ~approximately 2 x 1~3 colony forming units) suspension of the microl)es in sterile water. Incubation occurred for 24 hours at 37C in a humidified chamber. At the end of the incubation period the entire volume of each well was placed in a sterile test tube, vortexed, and serial one-hundred fold dilutions (10 to 10-6) were made for streaking onto sheep blood agar plates. Quantitative counts of colony forming units were made from these plates after 24 hours of incubation at 37C. Standard microbial techniques were used in maintaining stock cultures of organisms as well as preparing inoculums. Special media were used when sheep blood agar plates were not appropriate, e.g. Proteus vulgarls was plated onto eosin methylene blue (5% agar) plates to prevent colony spreading.
~2~ 73 In Vivo Testing The antimicrobial properties of the wound dressings of the invention are demonstrated in vivo using standard techni~ues as described below. Female Yorkshire pigs (Sus scrofa) were given preanesthetic doses of atropine sulfate and ketamine. Surgical plane anesthesia was induced with a gaseous mixture of halothane, nitrous oxide, and oxygen through an endotracheal tube. The dorsal ; skin was then washed, shaved, and swabbed with several applications of BetadineR (a registered trademark of the Purdue Frederick Company). The back of the pig was then covered with sterile surgical drapes leaving the setadineR
covered skin exposed. The final application of setadineR
was then repeatedly rinsed with sterile water to remove all traces of setadine , thus resulting in a sterile surgical 15 field. A 7.0 cm by 10.0 cm grid pattern was marked off on the skin to accommodate 16 dressings (6 cm by 7 cm). In the center of each grid, a l cm2 wound was created using a keratome. These wounds were approximately 0.5 to 1.0 mm deep. Each wound was then inoculated with 10~ liter (approximately 2 x 103 colony forming units) of the culture being tested. Immediately after inoculation, the wound dressing being tested was placed over the wound site.
Contrc71 wounds were covered with identical dressings which had not been coated with a silver salt. These inoculated wounds were left intact for 48 hours. Total surgical biopsy of the wounds occurred 48 hours post inoculation.
This biopsy consisted of removing the exudate from underneath the wound by sterile sylinge aspiration, swab removal of surface wound material, and surgical excision of the entire wound to a depth of approximately 3 mm. All samples from a single wound were placed in a sterile homogenizing tube, 3.0 ml of sterile phosphate buffered saline was added and then the samples were hand ground.
One-hundred fold dilutions of this homogenate were then plated out on sheep blood agar plates. The plates were incubated for 24 hours then quantitatively analyzed for the number of colony forming units per wound.
~^ .
~lZ~573 g It should be noted that moist healing conditions should be maintained in vivo to prevent the formation of a scab which can shield the bacteria of the colony from the antimicorbial film of a silver salt and thereby render the in vivo test inaccurate.
~o _Coating Procedure The articles described in the following examples were vapor coated in accordance with the procedure described above wherein the particulars set forth in the exemplary clauses (denoted hy e.g.) were those actually employed to prepare the articles described below.
The following examples are provided to illustrate the invention, but are not intended to limit the invention.
Examples 1-8 and Cornparative Examples A-D
TegadermR B _nd Dressing Vapor ~oated with Various Silver Salts The adhesive-side release liner was removed from a sample of TegadeLmR brand adhesive-coated, thin-film dressing and a 6.25 cm2 square was cut out of the release liner. This liner was then reapplied and the sample was subjected to vapor coating as described with the desired silver compound. However, the silver oxide of Example A
and the silver carbonate of Example s decomposed upon exposure to the electron beam used to vaporize the other silver salt samples. All samples were then tested for ln vitro efficacy against Staphylococcus aureus as described above. The results are summarized in Ta~le 1.
The efficacy ratings assigned in Table 1 are based on the following scale:
Efficacy Rating:
I = less than 103 colony forming units/ml II = 10 to 105 colony forming units/ml III = 106 to 107 colony forming units/ml IV = greater than or equal to 10 colony forming units/ml which is equivalent to the control Y~: ~
~;~7~
In vitro Efficacy of Vapor Coated Tegaderm~ Brand Dressing Against Staphylococcus aureus Film Thickness Efficacy 5 Example Compound (A) Rating 1 Silver fluoride 500 II
2 Silver bromide 500 II
3 Silver chloride 500 4 Silver nitrate 1100 Silver sulfate 100 6 Silver acetate 1000 7 Silver sulphadiazine<lO0 III
8 Silver p-toluenesulfonate <260 II
A Silver oxide none --B Silver carbonate none --C Silver iodide 500 IV
D Silver sulfide 1000 IV
Examples 9--20 In vitro Activity of Tegaderm Brand Dressin~ Vapor Coated with Silver Chloride Samples of TegadermR brand dressings were vapor coated as described in Example l with silver chloride to give coatings of 50 A, 125A, 250 A, and 500 A. These samples were tested in vitro against 8 different organisms.
The results are shown in Table 2.
Examples 21-23 In vivo Activity of Tegaderm Brand Dresslng Vapor Coated with Silver Chloride Samples of TegadermR brand dressings were vapor coated as described in Example l with silver chloride to give coatings of 500 A, 1000 A, and 2000 A. These samples were tested for ln vivo efficacy against Staphylococcus aureus. The results are shown in Table 3.
~Z7~;t73 In Vivo Study of the Efficacy of TeqadermR Brand Dressings Vapor Coated with Silver Chloride Against Staphylococcus Aureus s F i 1 m . Exa~ Thickness ~ of Colony_Forming Units Control -- 6.72 + 0.59 21 500 A 3.27 + 1.29**
22 1000 A 2 . 9S + O . 91**
: 10 23 2000 A 3.75 + 1.60*
Inoculum per wound was 2 x 19 colony forming units * Significant at 0.05 level in T-test ** Significant at 0.01 level in T-test Examples 24 and 25 In vitro Activity of_TegadermR Brand Dressings Vapor Coated with S lver Sulfate Samples of Tegadermn brand dressings were vapor ; 20 coated as described in Example 1 with silver sulfate to give coatings of 50 A and 230 A. These samples were tested for in vitro efficacy against S_aphylococcus aureus. The results are shown in Table 4.
:
In Vitro Efficacy of TegadermR Brand Dressings Vapor Coated with Silver Sulfate Against Staphylococcus Aureus ~, 30 Film Example Thickness Log of Colony Forming Units : Control -- 9.16 + 0.05 24 50 A 3.21 + 1.44*
230 A 2.97 + 1.42*
* Significant at 0.01 level in T-test .,, ~' ;r, ~ .
. :
' ~:79~i73 E am~es 26-36 In vitro Activity of Various Substrates Vapor Coated with . _ .
Silver Chloride Silver chloride was vapor coated onto a variety of substrates. These substrates were then tested for ln itro efficacy against Staphylococcus aureus. Uncoated Tegaderm~ brand dressing was used as a control. The results are shown in Table 5.
.,`
,, .
lZ'7~7~3 In vitro Study of the Efficacy Against Staphyloco _us_ ureus of Various Substrates Vapor Coated with 500 A of Silver Chloride Average Log of Exam~ SubstrateColony Forming Units Control* Tegaderm 9.60 26 Tegaderm 3.74 27 Nylon meshl 2.95 28 Non-woven mesh23.51 29 Non-woven mesh32.73 Fiberglass mesh4 2.53 31 Gauzes 2.33 32 Polyurethane foam6 3.04 33 Composite7 4.17 34 Composite8 1.72 Non-woven mesh91.18 36 Acetate meshl1.70 * No silver chloride film 1 CerexR - Nylon 6 from Monsanto Textiles Co., New York, NY
2 Nylon 90 available from Carolina Formed Fabrics Corporation 3 CarelleTM available from Carolina Formed Fabrics Corporation 4 orthopedic Products Division, 3M Company, St. Paul, MN
CurityR gauze sponges from the Kendal Company, Boston, MA
6 HypolTM foam available from W. R. Grace & Co., New York, NY
7 MicropadTM available f~om 3M Company, St. Paul, MN
8 BiobraneTM available from Woodruff Laboratories, Inc., Santa Ana, CA
9 N-Terface available from Winfield Laboratories, Inc., Richardson, TX
10 Available from Celanese Fibers Operation, Charlotte, NC.
1279~i73 Examples 37 and 38 In vitro Activity of Tegaderm Brand Dressing Sputter _ .
Coated with Varying Amounts of Silver Chloride The in vitro activity of TegadermR brand dressings sputter coated with silver chloride is shown in Table 6.
In Vitro Efficacy Against Staphylococcus aureus of Tegaderm~ Brand Dressing Sputter Coated with Silver Chloride Film Average Log of Example ThicknessColony Forming Units Control -- 9.47 + 0.11 15 37 500 A 4.59 ~ 0.87*
38 125 A 2.07 + 2.75*
* Significant at 0.01 level in T-test E mples 39 and 40 and Co~rative Examples E and F
In vivo Activi~y~of Vapor Coated or Powder Coated Silver Chloride Applied to TegardermR sral_d D essi_g With or Without Adhesive Samples of TegadermR brand dressing, with adhesive in Example 39 and without adhesive in Example 40, were vapor coated as described in Example 1 to give film coatings of 500 A. Powdered silver chloride was powder-coated onto TegadermR brand dressing with adhesive (Example E) and sodium chloride was vapor coated (~xample F), as described in Example 1, onto TegadermR brand dressing with adhesive to give a coating of 3200 A. The results are shown in Table 7.
~2'7~
TA~LE 7 In Vivo Activity of Vapor Coated or Powder Coated Silver Chloride Applied to TegadermR Brand Dressing With and Without Adhesive s Silver concentration Log of Colony Example Eorm (~g/cm ) Forming Units/ml Control -- -- 7.44 + 1.12 39 vapor coated 21 2.77 + 1.01 onto adhesive vapor coated 21 5.46 + 2.22 w/o adhesive E powder coated 120 5.88 + 2.62 onto adhesive F vapor coated --* 8.03 + 1.57 onto adhesive (Inoculum per wound s 1.2 x 103 cfu) * 434 ~g/cm of NaCl The dressing of Example 40 was not significantly more effective that the Control Example because the absence of the adhesive layer raised the moisture vapor transmission of the dressing to a level sufficient to allow the wound to dry and form a hardened scab, which hardened ;~ 30 scab shielded the bacteria from the silver chloride film.
A backside coating, or a layer of adhesive as illustrated in Example 39, can be added to the dressing to lower the moisture vapor transmission of the dressing and to maintain a moist wound while healing.
Analysis of the X-ray diffraction pattern of a ; film of silver chloride deposited on a representative 7~7~3 .
conformable substrate, i.e. TegadermR brand dressing, by vapor coating revealed that the crystals of silver chloride were highly oriented, e.g., cubic axes perpendicular to the substrate and (200) and 5400) planes parallel to the ` substrate, as compared with the relatively random orientation of the crystals of powdered silver chloride powder coated on an identical representative conformable substrate.
~ ~L~'7~S~73 a) a~ oo o ~ o ,~ ~ I~ ~ ~ oo' ) a~ o o ~ o ~r u~ ~ ~ r~
h O ~ o~
fi C ~ _ ~O a~ ~ u~ I` ~ co u~ In 0~ ~O ~r o ~1 ~ ~ ~ ~ o ~ o~
C Q r~ t~ r- ~fl r~ ~ N ~ ~) ~ rrt ~) ei~ r~) ~r 1~ (a ~1 ~1 t~ ~o ~r ~ o co o o ~ o n ~r o ~
~r3 ~ C ~ ~'1 ~ _ O ~ ~D O ~ O r~ ~ N ~ Ul a) ~
~) ~ ~
u~ 8 ~ ~ D o o ~ ~n o o o O~ ~D~1 ~O ~OO OW~ OOO
J- _I ~ b ~ ~) a~ co ~ ~ ~ ~ ~ ~ _ ,~ o o o o o 3 U~ a. ~ ..
JJ
U~
~ tn C tr) ,~
., :~ ~ ~ a~ ~ ~ co co ~ ~ O QO
E ~0 ~ . ~~ ~ _ r o o r~ u~ I
~: G ~ ~ ~ D r r ~D r r ~ er ~
'~ ~ ~u ~: ~ 8 s ~ u~ In o o o o o o o o o o o c~ .. ,.~1 o~ ooo ooo ooo ooo ~ ~u h ~1 h O S 8 ~n a~ o o o o o o o o o o o o r~
u~
~ 0 .~ ~ O ~ ~ U~ r o o o ~
w S ,,c~ N ~r r ~ N r o ~ ~r N ~) N
~ , ~ ~ o o a~ o u~ r co r r a~
~ p,a~
to r~l In _ O O O O O O ~ O ~ O~
o o o o o o a~ O ~r c~ _ ~ .
,~h~ 0~ a~ ~o o oo o o u~ _ 1~co a~ co ~n tq a) O ~ O .¢ o ':C ~
Y o o tn o ~ ~ I I Io U~
.~~1 I I IU) N .--1 ~ Sh ~1 ~ 1- ~~ O ~N ~ ~r 11 ) ~O 1`- CO a~ O
C C C _ ~1 _ ~1 _I _~ rl ~ ~ N
1~9 ~
8 Silver p-toluenesulfonate <260 II
A Silver oxide none --B Silver carbonate none --C Silver iodide 500 IV
D Silver sulfide 1000 IV
Examples 9--20 In vitro Activity of Tegaderm Brand Dressin~ Vapor Coated with Silver Chloride Samples of TegadermR brand dressings were vapor coated as described in Example l with silver chloride to give coatings of 50 A, 125A, 250 A, and 500 A. These samples were tested in vitro against 8 different organisms.
The results are shown in Table 2.
Examples 21-23 In vivo Activity of Tegaderm Brand Dresslng Vapor Coated with Silver Chloride Samples of TegadermR brand dressings were vapor coated as described in Example l with silver chloride to give coatings of 500 A, 1000 A, and 2000 A. These samples were tested for ln vivo efficacy against Staphylococcus aureus. The results are shown in Table 3.
~Z7~;t73 In Vivo Study of the Efficacy of TeqadermR Brand Dressings Vapor Coated with Silver Chloride Against Staphylococcus Aureus s F i 1 m . Exa~ Thickness ~ of Colony_Forming Units Control -- 6.72 + 0.59 21 500 A 3.27 + 1.29**
22 1000 A 2 . 9S + O . 91**
: 10 23 2000 A 3.75 + 1.60*
Inoculum per wound was 2 x 19 colony forming units * Significant at 0.05 level in T-test ** Significant at 0.01 level in T-test Examples 24 and 25 In vitro Activity of_TegadermR Brand Dressings Vapor Coated with S lver Sulfate Samples of Tegadermn brand dressings were vapor ; 20 coated as described in Example 1 with silver sulfate to give coatings of 50 A and 230 A. These samples were tested for in vitro efficacy against S_aphylococcus aureus. The results are shown in Table 4.
:
In Vitro Efficacy of TegadermR Brand Dressings Vapor Coated with Silver Sulfate Against Staphylococcus Aureus ~, 30 Film Example Thickness Log of Colony Forming Units : Control -- 9.16 + 0.05 24 50 A 3.21 + 1.44*
230 A 2.97 + 1.42*
* Significant at 0.01 level in T-test .,, ~' ;r, ~ .
. :
' ~:79~i73 E am~es 26-36 In vitro Activity of Various Substrates Vapor Coated with . _ .
Silver Chloride Silver chloride was vapor coated onto a variety of substrates. These substrates were then tested for ln itro efficacy against Staphylococcus aureus. Uncoated Tegaderm~ brand dressing was used as a control. The results are shown in Table 5.
.,`
,, .
lZ'7~7~3 In vitro Study of the Efficacy Against Staphyloco _us_ ureus of Various Substrates Vapor Coated with 500 A of Silver Chloride Average Log of Exam~ SubstrateColony Forming Units Control* Tegaderm 9.60 26 Tegaderm 3.74 27 Nylon meshl 2.95 28 Non-woven mesh23.51 29 Non-woven mesh32.73 Fiberglass mesh4 2.53 31 Gauzes 2.33 32 Polyurethane foam6 3.04 33 Composite7 4.17 34 Composite8 1.72 Non-woven mesh91.18 36 Acetate meshl1.70 * No silver chloride film 1 CerexR - Nylon 6 from Monsanto Textiles Co., New York, NY
2 Nylon 90 available from Carolina Formed Fabrics Corporation 3 CarelleTM available from Carolina Formed Fabrics Corporation 4 orthopedic Products Division, 3M Company, St. Paul, MN
CurityR gauze sponges from the Kendal Company, Boston, MA
6 HypolTM foam available from W. R. Grace & Co., New York, NY
7 MicropadTM available f~om 3M Company, St. Paul, MN
8 BiobraneTM available from Woodruff Laboratories, Inc., Santa Ana, CA
9 N-Terface available from Winfield Laboratories, Inc., Richardson, TX
10 Available from Celanese Fibers Operation, Charlotte, NC.
1279~i73 Examples 37 and 38 In vitro Activity of Tegaderm Brand Dressing Sputter _ .
Coated with Varying Amounts of Silver Chloride The in vitro activity of TegadermR brand dressings sputter coated with silver chloride is shown in Table 6.
In Vitro Efficacy Against Staphylococcus aureus of Tegaderm~ Brand Dressing Sputter Coated with Silver Chloride Film Average Log of Example ThicknessColony Forming Units Control -- 9.47 + 0.11 15 37 500 A 4.59 ~ 0.87*
38 125 A 2.07 + 2.75*
* Significant at 0.01 level in T-test E mples 39 and 40 and Co~rative Examples E and F
In vivo Activi~y~of Vapor Coated or Powder Coated Silver Chloride Applied to TegardermR sral_d D essi_g With or Without Adhesive Samples of TegadermR brand dressing, with adhesive in Example 39 and without adhesive in Example 40, were vapor coated as described in Example 1 to give film coatings of 500 A. Powdered silver chloride was powder-coated onto TegadermR brand dressing with adhesive (Example E) and sodium chloride was vapor coated (~xample F), as described in Example 1, onto TegadermR brand dressing with adhesive to give a coating of 3200 A. The results are shown in Table 7.
~2'7~
TA~LE 7 In Vivo Activity of Vapor Coated or Powder Coated Silver Chloride Applied to TegadermR Brand Dressing With and Without Adhesive s Silver concentration Log of Colony Example Eorm (~g/cm ) Forming Units/ml Control -- -- 7.44 + 1.12 39 vapor coated 21 2.77 + 1.01 onto adhesive vapor coated 21 5.46 + 2.22 w/o adhesive E powder coated 120 5.88 + 2.62 onto adhesive F vapor coated --* 8.03 + 1.57 onto adhesive (Inoculum per wound s 1.2 x 103 cfu) * 434 ~g/cm of NaCl The dressing of Example 40 was not significantly more effective that the Control Example because the absence of the adhesive layer raised the moisture vapor transmission of the dressing to a level sufficient to allow the wound to dry and form a hardened scab, which hardened ;~ 30 scab shielded the bacteria from the silver chloride film.
A backside coating, or a layer of adhesive as illustrated in Example 39, can be added to the dressing to lower the moisture vapor transmission of the dressing and to maintain a moist wound while healing.
Analysis of the X-ray diffraction pattern of a ; film of silver chloride deposited on a representative 7~7~3 .
conformable substrate, i.e. TegadermR brand dressing, by vapor coating revealed that the crystals of silver chloride were highly oriented, e.g., cubic axes perpendicular to the substrate and (200) and 5400) planes parallel to the ` substrate, as compared with the relatively random orientation of the crystals of powdered silver chloride powder coated on an identical representative conformable substrate.
~ ~L~'7~S~73 a) a~ oo o ~ o ,~ ~ I~ ~ ~ oo' ) a~ o o ~ o ~r u~ ~ ~ r~
h O ~ o~
fi C ~ _ ~O a~ ~ u~ I` ~ co u~ In 0~ ~O ~r o ~1 ~ ~ ~ ~ o ~ o~
C Q r~ t~ r- ~fl r~ ~ N ~ ~) ~ rrt ~) ei~ r~) ~r 1~ (a ~1 ~1 t~ ~o ~r ~ o co o o ~ o n ~r o ~
~r3 ~ C ~ ~'1 ~ _ O ~ ~D O ~ O r~ ~ N ~ Ul a) ~
~) ~ ~
u~ 8 ~ ~ D o o ~ ~n o o o O~ ~D~1 ~O ~OO OW~ OOO
J- _I ~ b ~ ~) a~ co ~ ~ ~ ~ ~ ~ _ ,~ o o o o o 3 U~ a. ~ ..
JJ
U~
~ tn C tr) ,~
., :~ ~ ~ a~ ~ ~ co co ~ ~ O QO
E ~0 ~ . ~~ ~ _ r o o r~ u~ I
~: G ~ ~ ~ D r r ~D r r ~ er ~
'~ ~ ~u ~: ~ 8 s ~ u~ In o o o o o o o o o o o c~ .. ,.~1 o~ ooo ooo ooo ooo ~ ~u h ~1 h O S 8 ~n a~ o o o o o o o o o o o o r~
u~
~ 0 .~ ~ O ~ ~ U~ r o o o ~
w S ,,c~ N ~r r ~ N r o ~ ~r N ~) N
~ , ~ ~ o o a~ o u~ r co r r a~
~ p,a~
to r~l In _ O O O O O O ~ O ~ O~
o o o o o o a~ O ~r c~ _ ~ .
,~h~ 0~ a~ ~o o oo o o u~ _ 1~co a~ co ~n tq a) O ~ O .¢ o ':C ~
Y o o tn o ~ ~ I I Io U~
.~~1 I I IU) N .--1 ~ Sh ~1 ~ 1- ~~ O ~N ~ ~r 11 ) ~O 1`- CO a~ O
C C C _ ~1 _ ~1 _I _~ rl ~ ~ N
1~9 ~
Claims (22)
1. An article useful as a wound dressing comprising a conformable substrate vapor coated with an antimicrobially effective film of silver chloride, said substrate having a low enough moisture vapor transmission to maintain a moist environment around the wound during healing so as to substantially prevent the formation of a hardened scab over the wound.
2. An article according to claim 1 wherein said film is from about 50 to about 2000 Angstroms in thickness.
3. An article according to claim 1 wherein the substrate is a fabric or a polymeric film or foam having a tensile modulus of less than about 400,000 psi.
4. An article according to claim 1 wherein the substrate is selected from the group consisting of an adhesive-coated, this film sheet, a polyurethane foam, a woven mesh and a non-woven mesh.
5. An article according to claim 1 wherein a coating of pressure-sensitive adhesive is disposed between said substrate and said antimicrobially effective film.
6. An article useful as a wound dressing comprising a conformable substrate vapor coated with an antimicrobially effective film of a silver arylsulfonate, said substrate having a low enough moisture vapor transmission to maintain a moist environment around the wound during healing so as to substantially prevent the formation of a hardened scab over the wound.
7. An article in accordance with claim 6 wherein said arylsulfonate is optionally substituted phenyl or naphthyl sulfonate.
8. An article in accordance with claim 6 wherein said arylsulfonate is an alkarylsufonate having 1 to 12 aliphatic carbon atoms.
9. An article in accordance with claim 6 wherein said arylsulfonate is phenyl or naphthyl sulfonate optionally substituted with alkyl groups having 1 to 4 carbon atoms.
10. An article in accordance with claim 6 wherein said silver arylsulfonate is silver toluenesulfonate.
11. An article in accordance with claim 10 wherein said silver toluenesulfonate is silver p-toluenesulfonate.
12. A method of preparing an antimicrobial wound dressing article comprising vapor coating a conformable substrate with an antimicrobially effective amount of a silver salt selected from the group consisting of silver fluoride, silver bromide, silver chloride, silver nitrate, silver sulphate, silver alkyl-carboxylate, silver sulphadiazine, or silver arylsulfonate, said substrate having a low enough moisture vapor transmission to maintain a moist environment around the wound during healing so as to substantially prevent the formation of a hardened scab over the wound.
13. A method of preparing an antimicrobial wound dressing article comprising sputter coating a conformable substrate with an antimicrobially effective amount of a silver salt selected from the group consisting of silver fluoride, silver bromide, silver chloride silver nitrate, silver sulfate, silver alkylcarboxylate, silver sulphadiazine, or silver arylsulfonate, said substrate having a low enough moisture vapor transmission to maintain a moist environment around the wound during healing so as to substantially prevent the formation of a hardened scab over the wound.
14. An article useful as a wound dressing comprising a conformable substrate vapor coated with an antimicrobially effective film of silver sulfate, said substrate having a low enough moisture vapor transmission to maintain a moist environment around the wound during healing so as to substantially prevent the formation of a hardened scab over the wound.
15. An article useful as a wound dressing comprising a conformable substrate vapor coated with an antimicrobially effective film of a silver alkylcarboxylate, said substrate having a low enough moisture vapor transmission to maintain a moist environment around the wound during healing so as to substantially prevent the formation of a hardened scab over the wound.
16. An article in accordance with claim 15 wherein said silver alkylcarboxylate is silver acetate.
17. An article in accordance with claim 15 wherein said alkylcarboxylate has from 1 to 12 aliphatic carbon atoms.
18. An article in accordance with claim 15 wherein said alkylcarboxylate has from 1 to 4 aliphatic carbon atoms.
19. An article useful as a wound dressing comprising a conformable substrate vapor coated with an antimicrobially effective film of silver nitrate, said substrate having a low enough moisture vapor transmission to maintain a moist environment around the wound during healing so as to substantially prevent the formation of a hardened scab over the wound.
20. An article useful as a wound dressing comprising a conformable substrate vapor coated with an antimicrobially effective film of silver fluoride, said substrate having a low enough moisture vapor transmission to maintain a moist environment
21 around the wound during healing so as to substantially prevent the formation of a hardened scab over the wound.
21. An article useful as a wound dressing comprising a conformable substrate vapor coated with an antimicrobially effective film of silver bromide, said substrate having a low enough moisture vapor transmission to maintain a moist environment around the wound during healing so as to substantially prevent the formation of a hardened scab over the wound.
21. An article useful as a wound dressing comprising a conformable substrate vapor coated with an antimicrobially effective film of silver bromide, said substrate having a low enough moisture vapor transmission to maintain a moist environment around the wound during healing so as to substantially prevent the formation of a hardened scab over the wound.
22. An article useful as a wound dressing comprising a conformable substrate vapor coated with an antimicrobially effective film of silver sulphadiazine, said substrate having a low enough moisture vapor transmission to maintain a moist environment around the wound during healing so as to substantially prevent the formation of a hardened scab over the wound.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US889,671 | 1986-07-24 | ||
US06/889,671 US4728323A (en) | 1986-07-24 | 1986-07-24 | Antimicrobial wound dressings |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1279573C true CA1279573C (en) | 1991-01-29 |
Family
ID=25395566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000539200A Expired - Fee Related CA1279573C (en) | 1986-07-24 | 1987-06-09 | Antimicrobial wound dressing |
Country Status (11)
Country | Link |
---|---|
US (1) | US4728323A (en) |
EP (1) | EP0255248B1 (en) |
JP (1) | JPH0824709B2 (en) |
KR (1) | KR950006936B1 (en) |
AU (1) | AU595333B2 (en) |
BR (1) | BR8703755A (en) |
CA (1) | CA1279573C (en) |
DE (1) | DE3780229T2 (en) |
ES (1) | ES2032827T3 (en) |
MX (1) | MX165268B (en) |
ZA (1) | ZA875427B (en) |
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5407685A (en) * | 1986-02-06 | 1995-04-18 | Steris Corporation | Controlled oxygen/anti-microbial release films |
EP0570452A1 (en) * | 1991-02-06 | 1993-11-24 | Minnesota Mining And Manufacturing Company | Improved surgical hardware with bacteriostatic silver coating, and method of using same |
BR9205879A (en) * | 1991-04-10 | 1994-07-05 | Christopher C Capelli | Antimicrobial composition, adhesive composition, mammalian infection treatment process and process for providing antimicrobial protection to a patient |
US5662913A (en) * | 1991-04-10 | 1997-09-02 | Capelli; Christopher C. | Antimicrobial compositions useful for medical applications |
US5120325A (en) * | 1991-06-12 | 1992-06-09 | Fleshtones Products Co., Inc. | Color-matched sterile adhesive bandages containing melanin-like pigment composition |
MX9302110A (en) * | 1992-04-15 | 1994-05-31 | Schuller Int Inc | AIR FILTER AND METHOD TO REDUCE THE AMOUNT OF MICROORGANISMS IN CONTAMINATED AIR. |
US6685682B1 (en) | 1993-03-22 | 2004-02-03 | 3M Innovative Properties Company | Carrier delivered dressing and method of manufacture |
DE69426230T2 (en) | 1993-03-22 | 2001-03-01 | Minnesota Mining & Mfg | DISPENSING BANDAGE AND MANUFACTURING PROCESS WITH A WINDOW-FREE FRAME |
US5534288A (en) * | 1993-03-23 | 1996-07-09 | United States Surgical Corporation | Infection-resistant surgical devices and methods of making them |
US5848995A (en) * | 1993-04-09 | 1998-12-15 | Walder; Anthony J. | Anti-infective medical article and method for its preparation |
US5905092A (en) * | 1994-09-27 | 1999-05-18 | Virotex Corporation Reel/Frame | Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction |
US5631301A (en) * | 1994-09-27 | 1997-05-20 | Virotex Corporation | Topical antibiotic composition providing optimal moisture environment |
US5810755A (en) * | 1994-10-17 | 1998-09-22 | Leveen; Harry H. | Medicated wound dressing |
US5814094A (en) * | 1996-03-28 | 1998-09-29 | Becker; Robert O. | Iontopheretic system for stimulation of tissue healing and regeneration |
US6861570B1 (en) | 1997-09-22 | 2005-03-01 | A. Bart Flick | Multilayer conductive appliance having wound healing and analgesic properties |
US6087549A (en) * | 1997-09-22 | 2000-07-11 | Argentum International | Multilayer laminate wound dressing |
US8455710B2 (en) * | 1997-09-22 | 2013-06-04 | Argentum Medical, Llc | Conductive wound dressings and methods of use |
US8801681B2 (en) | 1995-09-05 | 2014-08-12 | Argentum Medical, Llc | Medical device |
US7214847B1 (en) * | 1997-09-22 | 2007-05-08 | Argentum Medical, L.L.C. | Multilayer conductive appliance having wound healing and analgesic properties |
DE19631421C2 (en) * | 1996-08-06 | 2002-07-18 | Beiersdorf Ag | Antimicrobial wound dressings |
US5976117A (en) | 1996-09-25 | 1999-11-02 | 3M Innovative Properties Company | Wound dressing |
US6800278B1 (en) | 1996-10-28 | 2004-10-05 | Ballard Medical Products, Inc. | Inherently antimicrobial quaternary amine hydrogel wound dressings |
US6039940A (en) * | 1996-10-28 | 2000-03-21 | Ballard Medical Products | Inherently antimicrobial quaternary amine hydrogel wound dressings |
US6333093B1 (en) | 1997-03-17 | 2001-12-25 | Westaim Biomedical Corp. | Anti-microbial coatings having indicator properties and wound dressings |
US5782788A (en) * | 1997-03-21 | 1998-07-21 | Widemire; Dewitt P. | Wound dressing |
GB9713023D0 (en) * | 1997-06-20 | 1997-08-27 | Reckitt & Colmann Prod Ltd | Improvements in or relating to the cleansing of surfaces |
US6153210A (en) * | 1997-08-14 | 2000-11-28 | Periodontix, Inc. | Use of locally delivered metal ions for treatment of periodontal disease |
US6458109B1 (en) | 1998-08-07 | 2002-10-01 | Hill-Rom Services, Inc. | Wound treatment apparatus |
US6168800B1 (en) | 1998-08-20 | 2001-01-02 | Medwrap Corporation | Antimcrobial multi-layer island dressing |
US6596401B1 (en) | 1998-11-10 | 2003-07-22 | C. R. Bard Inc. | Silane copolymer compositions containing active agents |
US7709694B2 (en) * | 1998-12-08 | 2010-05-04 | Quick-Med Technologies, Inc. | Materials with covalently-bonded, nonleachable, polymeric antimicrobial surfaces |
US7045673B1 (en) | 1998-12-08 | 2006-05-16 | Quick-Med Technologies, Inc. | Intrinsically bactericidal absorbent dressing and method of fabrication |
US20050033251A1 (en) * | 1998-12-08 | 2005-02-10 | Quick-Med Technologies, Inc. | Controlled release of biologically active substances from select substrates |
DE19958697A1 (en) * | 1999-12-06 | 2001-06-07 | Basf Ag | Absorbent preparation |
US7179849B2 (en) | 1999-12-15 | 2007-02-20 | C. R. Bard, Inc. | Antimicrobial compositions containing colloids of oligodynamic metals |
US6716895B1 (en) | 1999-12-15 | 2004-04-06 | C.R. Bard, Inc. | Polymer compositions containing colloids of silver salts |
US6579539B2 (en) | 1999-12-22 | 2003-06-17 | C. R. Bard, Inc. | Dual mode antimicrobial compositions |
AU2001250875A1 (en) * | 2000-03-30 | 2001-10-15 | Brennen Medical, Inc. | Anti-microbial and immunostimulating composition |
EP1294325B1 (en) * | 2000-05-22 | 2008-09-10 | Arthur C. Coffey | Combination sis and vacuum bandage |
US6369289B1 (en) | 2000-07-07 | 2002-04-09 | Tyco Healthcare Group Lp | Method and manufacture of a wound dressing for covering an open wound |
CA2343440A1 (en) * | 2000-07-13 | 2002-01-13 | G. Alan Thompson | Ultrasonic process for autocatalytic deposition of metal |
US20040191329A1 (en) * | 2000-07-27 | 2004-09-30 | Burrell Robert E. | Compositions and methods of metal-containing materials |
US20030180379A1 (en) * | 2000-07-27 | 2003-09-25 | Burrell Robert E. | Solutions and aerosols of metal-containing compounds |
US6855135B2 (en) | 2000-11-29 | 2005-02-15 | Hill-Rom Services, Inc. | Vacuum therapy and cleansing dressing for wounds |
US6685681B2 (en) * | 2000-11-29 | 2004-02-03 | Hill-Rom Services, Inc. | Vacuum therapy and cleansing dressing for wounds |
AU2002219937B9 (en) * | 2000-11-29 | 2006-03-16 | Convatec Technologies Inc. | Light stabilized antimicrobial materials |
US7157614B1 (en) | 2000-12-21 | 2007-01-02 | Fountainhead, Llc | Treatment devices providing targeted antimicrobial action |
US6437755B1 (en) | 2001-01-05 | 2002-08-20 | Ashok V. Joshi | Ionic shield for devices that emit radiation |
MXPA04002231A (en) † | 2001-09-12 | 2005-03-07 | Acordis Speciality Fibres Ltd | Antibacterial wound dressing. |
GB0127786D0 (en) * | 2001-11-20 | 2002-01-09 | Univ Nottingham | Impregnation of antimicrobial substances |
CN1612804A (en) * | 2001-12-03 | 2005-05-04 | C·R·巴德公司 | Microbe-resistant medical device, microbe-resistant polymeric coating and methods for producing same |
ATE387919T1 (en) * | 2001-12-26 | 2008-03-15 | Hill Rom Services Inc | VACUUM BAND PACKAGING |
US7005031B2 (en) * | 2002-01-16 | 2006-02-28 | 3M Innovative Properties Company | Pressure sensitive adhesives having quaternary ammonium functionality, articles, and methods |
US6835311B2 (en) * | 2002-01-31 | 2004-12-28 | Koslow Technologies Corporation | Microporous filter media, filtration systems containing same, and methods of making and using |
US7287650B2 (en) * | 2002-01-31 | 2007-10-30 | Kx Technologies Llc | Structures that inhibit microbial growth |
DE10218147B4 (en) * | 2002-04-23 | 2005-12-22 | Stockhausen Gmbh | Water-absorbing polymer particles retarding decomposition of body fluids, their preparation and use |
EP1496825B1 (en) * | 2002-04-23 | 2018-05-16 | Argentum Medical, LLC | Conductive wound dressings and methods of use |
US6923320B2 (en) | 2002-07-06 | 2005-08-02 | Victor A. Grossman | Bandage package and dispenser |
US8112973B2 (en) | 2002-10-04 | 2012-02-14 | Ethicon, Inc. | Method of making a packaged antimicrobial suture |
US7513093B2 (en) | 2002-10-04 | 2009-04-07 | Ethicon, Inc. | Method of preparing a packaged antimicrobial medical device |
US8133437B2 (en) | 2002-10-04 | 2012-03-13 | Ethicon, Inc. | Method of preparing an antimicrobial packaged medical device |
US9597067B2 (en) | 2002-10-04 | 2017-03-21 | Ethicon, Inc. | Packaged antimicrobial medical device and method of preparing same |
US9474524B2 (en) | 2002-10-04 | 2016-10-25 | Ethicon, Inc. | Packaged antimicrobial medical device having improved shelf life and method of preparing same |
US20040220614A1 (en) * | 2002-10-04 | 2004-11-04 | Howard Scalzo | Packaged antimicrobial medical device and method of preparing same |
US20040068293A1 (en) * | 2002-10-04 | 2004-04-08 | Howard Scalzo | Packaged antimicrobial medical device and method of preparing same |
DE10306187B4 (en) * | 2003-02-13 | 2005-08-04 | Steffen Barth | plaster |
DE10309558A1 (en) * | 2003-03-04 | 2004-09-23 | Nanoparc Gmbh | Antimicrobial surface-modified bandages for wound treatment, e.g. of burns, have a healing and a cell growth stimulating effect and have a chemical element integrated in the surface and molecularly bonded |
US7285576B2 (en) * | 2003-03-12 | 2007-10-23 | 3M Innovative Properties Co. | Absorbent polymer compositions, medical articles, and methods |
US20040180093A1 (en) * | 2003-03-12 | 2004-09-16 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US7112713B2 (en) * | 2003-03-12 | 2006-09-26 | Gelsus Research And Consulting, Inc. | Dressing based on the Teorell-Meyer gradient |
US20040181183A1 (en) * | 2003-03-12 | 2004-09-16 | Sceusa Nicholas A. | Bandage based on the teorell-meyer gradient |
US20040220534A1 (en) * | 2003-04-29 | 2004-11-04 | Martens Paul W. | Medical device with antimicrobial layer |
CA2460585A1 (en) * | 2003-05-16 | 2004-11-16 | Exciton Technologies Inc. | Deposition products, composite materials and processes for the production thereof |
US20050035327A1 (en) * | 2003-08-14 | 2005-02-17 | Canada T. Andrew | Topical silver-based antimicrobial composition for wound care devices |
US20050147657A1 (en) * | 2003-08-14 | 2005-07-07 | Milliken & Company | White silver-containing wound care device |
US7842306B2 (en) | 2003-08-14 | 2010-11-30 | Milliken & Company | Wound care device having fluid transfer properties |
US20050037057A1 (en) * | 2003-08-14 | 2005-02-17 | Schuette Robert L. | Silver-containing antimicrobial fabric |
US8563447B2 (en) * | 2003-08-14 | 2013-10-22 | Milliken & Company | Silver-containing wound care device |
US7118761B2 (en) | 2003-08-14 | 2006-10-10 | Canada T Andrew | Method for producing a silver-containing wound care device |
WO2005027834A2 (en) * | 2003-09-12 | 2005-03-31 | Z-Medica Corporation | Partially hydrated hemostatic agent |
US7745509B2 (en) * | 2003-12-05 | 2010-06-29 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US20050123621A1 (en) * | 2003-12-05 | 2005-06-09 | 3M Innovative Properties Company | Silver coatings and methods of manufacture |
US20050123590A1 (en) * | 2003-12-05 | 2005-06-09 | 3M Innovative Properties Company | Wound dressings and methods |
US20050152955A1 (en) * | 2003-12-16 | 2005-07-14 | Akhave Jay R. | Electrostatically self-assembled antimicrobial coating for medical applications |
DE102004001594B4 (en) * | 2004-01-09 | 2006-09-21 | Bio-Gate Ag | Wound dressing and process for its preparation |
CA2564822A1 (en) * | 2004-04-30 | 2005-11-17 | Burrell E. Clawson | Apparatus and methods for isolating human body areas for localized cooling |
US10251392B2 (en) | 2004-07-30 | 2019-04-09 | Avent, Inc. | Antimicrobial devices and compositions |
US20060035039A1 (en) * | 2004-08-12 | 2006-02-16 | 3M Innovative Properties Company | Silver-releasing articles and methods of manufacture |
US20060034899A1 (en) * | 2004-08-12 | 2006-02-16 | Ylitalo Caroline M | Biologically-active adhesive articles and methods of manufacture |
CA2529236A1 (en) * | 2004-12-07 | 2006-06-07 | Centre Des Technologies Textiles | New antimicrobial material |
US7506760B2 (en) * | 2005-01-10 | 2009-03-24 | Grossman Victor A | Packaging and dispensers for adhesive backed elements |
US20060178609A1 (en) | 2005-02-09 | 2006-08-10 | Z-Medica, Llc | Devices and methods for the delivery of molecular sieve materials for the formation of blood clots |
CA2597940A1 (en) | 2005-02-15 | 2006-08-24 | Virginia Commonwealth University | Mineral technologies (mt) for acute hemostasis and for the treatment of acute wounds and chronic ulcers |
US9326995B2 (en) * | 2005-04-04 | 2016-05-03 | The Regents Of The University Of California | Oxides for wound healing and body repair |
US8399027B2 (en) * | 2005-04-14 | 2013-03-19 | 3M Innovative Properties Company | Silver coatings and methods of manufacture |
FR2889649A1 (en) * | 2005-08-11 | 2007-02-16 | Eastman Kodak Co | Use of a dispersion of silver in imogolite and/or allophane matrix as antiseptic agent for the manufacture of bandages |
US20070048249A1 (en) | 2005-08-24 | 2007-03-01 | Purdue Research Foundation | Hydrophilized bactericidal polymers |
US20070095661A1 (en) * | 2005-10-31 | 2007-05-03 | Yi Wang | Method of making, and, analyte sensor |
GB0525504D0 (en) | 2005-12-14 | 2006-01-25 | Bristol Myers Squibb Co | Antimicrobial composition |
US20070154505A1 (en) * | 2005-12-30 | 2007-07-05 | Manico Joseph A | Antimicrobial agent to inhibit the growth of microorganisms on building materials |
US20070154506A1 (en) * | 2005-12-30 | 2007-07-05 | Patton David L | Antimicrobial agent to inhibit the growth of microorganisms on disposable products |
US20070161936A1 (en) * | 2006-01-06 | 2007-07-12 | Svetlik Harvey E | Wound treatment-dressing and method of manufacture |
US20070166399A1 (en) | 2006-01-13 | 2007-07-19 | 3M Innovative Properties Company | Silver-containing antimicrobial articles and methods of manufacture |
KR100814973B1 (en) * | 2006-03-29 | 2008-03-20 | (주) 월드비젼 | Method for manufacturing of band with silver and band manufactured method thereof |
US7261867B1 (en) | 2006-04-07 | 2007-08-28 | Eastman Kodak Company | Production of silver sulfate grains using organo-sulfate or organo-sulfonate additives |
US20070243258A1 (en) * | 2006-04-13 | 2007-10-18 | 3M Innovative Properties Company | Method and apparatus for forming crosslinked chromonic nanoparticles |
US8938898B2 (en) | 2006-04-27 | 2015-01-27 | Z-Medica, Llc | Devices for the identification of medical products |
GB0608437D0 (en) | 2006-04-28 | 2006-06-07 | Adv Med Solutions Ltd | Wound dressings |
US7604819B2 (en) | 2006-05-26 | 2009-10-20 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US7968114B2 (en) | 2006-05-26 | 2011-06-28 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US8202532B2 (en) | 2006-05-26 | 2012-06-19 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US20100098949A1 (en) * | 2006-10-18 | 2010-04-22 | Burton Scott A | Antimicrobial articles and method of manufacture |
US8703634B2 (en) * | 2007-02-21 | 2014-04-22 | The Regents Of The University Of California | Hemostatic compositions and methods of use |
US7931880B2 (en) * | 2007-03-30 | 2011-04-26 | Eastman Kodak Company | Production of silver sulfate grains using inorganic additives |
US20080317831A1 (en) * | 2007-06-21 | 2008-12-25 | Denny Lo | Hemostatic sponge and method of making the same |
ITPN20070030U1 (en) * | 2007-09-24 | 2009-03-25 | Abe Sport Group S R L | "ADHESIVE MEDICAL ARTICLE INCLUDING AT LEAST ONE LAYER OF ANTIBACTERIAL MATERIAL" |
US20090104252A1 (en) * | 2007-10-19 | 2009-04-23 | Scar Consultants, Llc | Wound dressing for improving scarring |
US7655212B2 (en) * | 2008-04-11 | 2010-02-02 | Eastman Kodak Company | Production of silver sulfate grains using a fluorinated additive |
US8062615B2 (en) * | 2008-04-11 | 2011-11-22 | Eastman Kodak Company | Production of silver sulfate grains using carboxylic acid additives |
US20100221313A1 (en) * | 2008-12-01 | 2010-09-02 | Innovative Pharmaceuticals, Llc | Transdermal reservoir patch |
US8858969B2 (en) | 2010-09-22 | 2014-10-14 | Z-Medica, Llc | Hemostatic compositions, devices, and methods |
GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
US20120282320A1 (en) * | 2011-05-05 | 2012-11-08 | George H. Scherr Trust | Hemostatic dressing |
WO2013026879A1 (en) * | 2011-08-23 | 2013-02-28 | Birgit Riesinger | Absorbent hygienic or personal care product having a strip-like component with a content of at least one heavy metal present in elemental or ionic form |
EP2573215A1 (en) * | 2011-09-20 | 2013-03-27 | Mölnlycke Health Care AB | Polymer fibers |
IN2014CN04311A (en) | 2011-12-13 | 2015-09-04 | 3M Innovative Properties Co | |
US10245025B2 (en) | 2012-04-06 | 2019-04-02 | Ethicon, Inc. | Packaged antimicrobial medical device having improved shelf life and method of preparing same |
PL2854723T3 (en) * | 2012-05-25 | 2017-12-29 | Coloplast A/S | Comfort layer for a collecting bag |
AU2013277643B2 (en) | 2012-06-22 | 2015-09-10 | Teleflex Life Sciences Ii Llc | Hemostatic devices |
US20150354096A1 (en) | 2012-12-20 | 2015-12-10 | Convatec Technologies Inc. | Processing of chemically modified cellulosic fibres |
US10376541B2 (en) * | 2014-01-27 | 2019-08-13 | Aidance Skincare & Topical Solutions Llc | Topical antibiotic formulations |
MX2016009696A (en) * | 2014-01-27 | 2017-03-27 | Aidance Skincare & Topical Solutions Llc | Topical antibiotic formulations. |
ES2921990T3 (en) | 2014-09-10 | 2022-09-05 | Bard Inc C R | Protective dressing for a medical device placed on the skin |
EP2995324A1 (en) * | 2014-09-11 | 2016-03-16 | Mölnlycke Health Care AB | Medical dressing |
EP2995287A1 (en) * | 2014-09-11 | 2016-03-16 | Mölnlycke Health Care AB | Medical dressing |
US20170231821A1 (en) * | 2016-01-19 | 2017-08-17 | Kci Usa, Inc. | Silicone wound contact layer with silver |
US20180340046A1 (en) | 2017-05-27 | 2018-11-29 | Poly Group LLC | Dispersible antimicrobial complex and coatings therefrom |
US20180362678A1 (en) | 2017-06-16 | 2018-12-20 | Poly Group LLC | Polymeric antimicrobial surfactant |
GB201711183D0 (en) | 2017-07-12 | 2017-08-23 | Smith & Nephew | Antimicrobial or wound care materials, devices and uses |
GB201711181D0 (en) | 2017-07-12 | 2017-08-23 | Smith & Nephew | Polymer foam material, device and use |
GB2568101B (en) * | 2017-11-06 | 2022-09-07 | Brightwake Ltd | Antimicrobial dressing |
KR102513326B1 (en) * | 2020-12-17 | 2023-03-23 | 주식회사 에코넷코리아 | virus inactivated fabrics and virus inactivated laminated fabric |
WO2022146850A1 (en) * | 2020-12-30 | 2022-07-07 | Falco Andrew | Snap band dressing devices and methods of use |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2838045A (en) * | 1956-10-29 | 1958-06-10 | Nat Aluminate Corp | Microbicidal bandage |
US2934066A (en) * | 1957-05-11 | 1960-04-26 | Lohmann Kg | Metallized bandaging material especially for the treatment of wounds |
US3249109A (en) * | 1963-11-01 | 1966-05-03 | Maeth Harry | Topical dressing |
US3830908A (en) * | 1971-07-23 | 1974-08-20 | H Margraf | Anti-microbial compositions utilizing allantoin compounds and complexes |
US3800792A (en) * | 1972-04-17 | 1974-04-02 | Johnson & Johnson | Laminated collagen film dressing |
US3903882A (en) * | 1974-04-19 | 1975-09-09 | American Cyanamid Co | Composite dressing |
EP0011471B1 (en) * | 1978-11-17 | 1983-02-09 | SMITH & NEPHEW RESEARCH LIMITED | Adhesive-coated sheet material incorporating anti-bacterial substances |
JPS55137654U (en) * | 1979-03-20 | 1980-10-01 | ||
JPS56148965A (en) * | 1980-04-17 | 1981-11-18 | Mitsubishi Rayon Co | Durable sterilizable fiber |
US4387156A (en) * | 1981-02-04 | 1983-06-07 | Minnesota Mining And Manufacturing Company | Imageable film containing a metal oxide opacifying layer |
GB2092006A (en) * | 1981-02-04 | 1982-08-11 | Landstingens Inkopscentral | Germicidal dressing |
US4364995A (en) * | 1981-02-04 | 1982-12-21 | Minnesota Mining And Manufacturing Company | Metal/metal oxide coatings |
US4419091A (en) * | 1981-02-12 | 1983-12-06 | Sybron Corporation | Metalized medical treatment electrode with insulated edge |
GB2093702B (en) * | 1981-02-13 | 1985-07-10 | Smith & Nephew Ass | Wound dressings for burns |
US4643179A (en) * | 1981-03-25 | 1987-02-17 | Wang Paul Y | Wound coverings and processes for their preparation |
US4466431A (en) * | 1981-05-09 | 1984-08-21 | Smith And Nephew Associated Companies Limited | Dressings, manufacture and use |
US4376764A (en) * | 1981-08-10 | 1983-03-15 | Basf Wyandotte Corporation | Silver ion gel compositions |
CA1212879A (en) * | 1982-07-21 | 1986-10-21 | Laszlo Juhasz | Composite wound dressing |
DE3228851A1 (en) * | 1982-08-02 | 1984-02-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München | Wound dressing |
JPS5937956A (en) * | 1982-08-24 | 1984-03-01 | カネボウ株式会社 | Particle filled fiber structure |
GR79380B (en) * | 1982-09-28 | 1984-10-22 | Johnson & Johnson Prod Inc | |
US4588400A (en) * | 1982-12-16 | 1986-05-13 | Johnson & Johnson Products, Inc. | Liquid loaded pad for medical applications |
GB2134791B (en) * | 1983-02-11 | 1987-05-20 | Vernon Carus Ltd | Antibacterial dressing |
US4446124A (en) * | 1983-03-31 | 1984-05-01 | Fox Jr Charles L | Wound dressing comprising silver sulfadiazine incorporated in animal tissue |
EP0122085B1 (en) * | 1983-04-06 | 1987-06-24 | Smith and Nephew Associated Companies p.l.c. | Dressing |
US4563184A (en) * | 1983-10-17 | 1986-01-07 | Bernard Korol | Synthetic resin wound dressing and method of treatment using same |
US4886505A (en) * | 1985-06-07 | 1989-12-12 | Becton, Dickinson And Company | Antimicrobial surfaces and inhibition of microorganism growth thereby |
-
1986
- 1986-07-24 US US06/889,671 patent/US4728323A/en not_active Expired - Lifetime
-
1987
- 1987-06-09 CA CA000539200A patent/CA1279573C/en not_active Expired - Fee Related
- 1987-06-16 AU AU74279/87A patent/AU595333B2/en not_active Ceased
- 1987-07-07 DE DE8787305992T patent/DE3780229T2/en not_active Expired - Lifetime
- 1987-07-07 ES ES198787305992T patent/ES2032827T3/en not_active Expired - Lifetime
- 1987-07-07 EP EP87305992A patent/EP0255248B1/en not_active Expired - Lifetime
- 1987-07-20 BR BR8703755A patent/BR8703755A/en not_active Application Discontinuation
- 1987-07-21 MX MX007445A patent/MX165268B/en unknown
- 1987-07-23 KR KR1019870007995A patent/KR950006936B1/en active IP Right Grant
- 1987-07-23 ZA ZA875427A patent/ZA875427B/en unknown
- 1987-07-23 JP JP62184651A patent/JPH0824709B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0255248B1 (en) | 1992-07-08 |
JPS6335260A (en) | 1988-02-15 |
US4728323A (en) | 1988-03-01 |
JPH0824709B2 (en) | 1996-03-13 |
DE3780229T2 (en) | 1993-01-28 |
AU595333B2 (en) | 1990-03-29 |
EP0255248A3 (en) | 1988-12-14 |
BR8703755A (en) | 1988-03-29 |
KR950006936B1 (en) | 1995-06-26 |
MX165268B (en) | 1992-11-04 |
AU7427987A (en) | 1988-01-28 |
KR880001304A (en) | 1988-04-22 |
ZA875427B (en) | 1989-03-29 |
DE3780229D1 (en) | 1992-08-13 |
ES2032827T3 (en) | 1993-03-01 |
EP0255248A2 (en) | 1988-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1279573C (en) | Antimicrobial wound dressing | |
EP0564503B1 (en) | Actively sterile surfaces | |
US6365220B1 (en) | Process for production of actively sterile surfaces | |
US5584801A (en) | Wound covering | |
CA2136454C (en) | Process of activating anti-microbial materials | |
EP0739219B1 (en) | Catheter having a long-lasting antimicrobial surface treatment | |
Sioshansi | New processes for surface treatment of catheters | |
CA1219209A (en) | Wound dressing comprising silver sulfadiazine incorporated in animal tissue | |
Neumann et al. | Gelatin‐based sprayable foam as a skin substitute | |
US20070179522A1 (en) | Multilayer wound dressing | |
US20180093008A1 (en) | Anti-microbial articles and methods of using same | |
US10639395B2 (en) | Anti-microbial articles and methods of using same | |
KR102258069B1 (en) | Novel medical countermeasure for first responder use in burn injury | |
UA46720C2 (en) | METHOD FOR PRODUCING ANTIMICROBIAL MATERIAL way to achieve antimicrobial effect, antimicrobial FORM SILVER MATERIAL grained antimicrobial materials and fine-grained antimicrobial METHOD FOR PRODUCING MATERIAL | |
EP1019104A1 (en) | Cell culture products | |
London et al. | Textile composite wound dressing | |
CN112274687B (en) | Stable hydrocolloid oil yarn and preparation method thereof | |
Juknius | Applications of diamond like carbon and silver nanocomposites for preparation of external use pharmaceuticals | |
EP4326352A1 (en) | A wound care product comprising an antimicrobial coating | |
Jose | Development of Antimicrobial Conjugates and Evaluating its Antibacterial potential and Wound Healing ability | |
RU2265454C1 (en) | Method for post-operational treatment of donor's wounds | |
JPH04272764A (en) | Wound coating material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKLA | Lapsed |